Corium International (CORI) Upgraded by BidaskClub to “Sell”

BidaskClub upgraded shares of Corium International (NASDAQ:CORI) from a strong sell rating to a sell rating in a research note published on Wednesday morning.

Several other equities research analysts also recently issued reports on CORI. Zacks Investment Research upgraded shares of Corium International from a hold rating to a buy rating and set a $13.00 price objective for the company in a research report on Thursday, March 22nd. Cantor Fitzgerald restated a buy rating and set a $14.00 price objective on shares of Corium International in a research report on Tuesday, March 27th. ValuEngine upgraded shares of Corium International from a hold rating to a buy rating in a research report on Monday, April 2nd. Finally, HC Wainwright set a $14.00 target price on shares of Corium International and gave the stock a buy rating in a report on Tuesday, May 15th. Two research analysts have rated the stock with a sell rating and six have issued a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $13.00.

Shares of CORI stock opened at $9.12 on Wednesday. The company has a debt-to-equity ratio of 1.89, a current ratio of 8.11 and a quick ratio of 7.95. The company has a market cap of $322.92 million, a price-to-earnings ratio of -5.56 and a beta of 1.54. Corium International has a 12-month low of $6.95 and a 12-month high of $13.93.

Corium International (NASDAQ:CORI) last issued its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.04). The company had revenue of $10.06 million for the quarter, compared to analyst estimates of $7.07 million. Corium International had a negative return on equity of 273.01% and a negative net margin of 156.05%. sell-side analysts anticipate that Corium International will post -1.59 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC increased its holdings in shares of Corium International by 14.0% during the fourth quarter. Renaissance Technologies LLC now owns 96,900 shares of the biopharmaceutical company’s stock worth $931,000 after purchasing an additional 11,900 shares during the period. Geode Capital Management LLC increased its holdings in shares of Corium International by 6.0% during the fourth quarter. Geode Capital Management LLC now owns 223,536 shares of the biopharmaceutical company’s stock worth $2,147,000 after purchasing an additional 12,745 shares during the period. MetLife Investment Advisors LLC bought a new position in shares of Corium International during the fourth quarter worth approximately $123,000. DekaBank Deutsche Girozentrale bought a new position in Corium International in the first quarter valued at approximately $167,000. Finally, Schwab Charles Investment Management Inc. increased its stake in Corium International by 47.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock valued at $476,000 after acquiring an additional 15,909 shares during the last quarter. 95.07% of the stock is currently owned by institutional investors.

About Corium International

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit